云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer 2021-01-06 21:54
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer 2021-01-06 21:52
1 3 4 5 6 7